Biotron Limited · ASX:BIT
Biotron — Biotech Showcase, Melbourne (September 2026)
12 slides from Biotron's conference presentation, Sep 3, 2026
Slide 1: Presentation to Investors - ASX cover letter
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: mmora@miscorp.com.au Website: www.biotron.com.au 3 September 2026 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (12 pages by email) For personal use only Dear Sir, PRESENTATION TO INVES
Slide 2: Investor Update
For personal use only INVESTOR UPDATE ASX:BIT | September 2026
Slide 3: Forward Looking Statement
This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. For personal use only FORWARD These statements are statement
Slide 4: Expanded and Diversified Drug Portfolio Provides Multiple Opportunities for Success
Expanded and Diversified Drug Portfolio Provides Multiple Opportunities for Success For personal use only Dec 2025 acquisition SedRx provides potential Continued, high potential Sedarex Ltd with next- fast, low risk antiviral program – generation general commercialisation pathway designing Phase 1 t
Slide 5: Biotron: A Diversified Development Portfolio
Biotron - Advanced Pipeline Biotron: A Diversified Development Portfolio Candidate Indication Discovery Nonclinical Phase 1 Phase 2 Phase 3 Focused on Ph 3 & progression to a SedRxTM General Anaesthesia marketing application in For personal use only Europe/UK Additional neurological SedRxTM indicati
Slide 6: SedRx: A Safer, Validated and Differentiated General Anaesthetic
SedRx: A Safer, Validated and Differentiated General Anaesthetic with Potential Fast Path to Market • SedRx: Reformulated safer general anaesthetic: Demand is driven by: • Proven Active Pharmaceutical Ingredient (API), For personal use only Ageing population Alfaxalone, used in millions of people &
Slide 7: SedRx: The ideal anaesthetic especially in an aging population
SedRx: The ideal anaesthetic especially in an aging population SedRx clinical experience: SedRx Propofol Fluranes - Effective & safer than propofol Rapid sleep onset - SedRx delivered better recovery of For personal use only Fast wakeup cognition & preservation of brain derived Improved CVS safety n
Slide 8: BIT-HBV001: Investment opportunity as a suppressive as well as a functional cure HBV therapy
BIT-HBV001: Investment opportunity as a suppressive as well as a “functional cure” HBV therapy Existing drugs treat HBV, but don’t eradicate B I T- H B V 0 0 1 the virus, so patients with chronic HBV infection remain at risk of progression to end- New class of drug with differentiated mode of stage
Slide 9: Biotron: Anticipated Milestones 2026/27
Biotron: Anticipated Milestones 2026/27 Determination of regulatory pathway for general anaesthetic product with European COMPLETED Medicines Agency (EMA) EMA feedback on design of pivotal Phase 3 trial and additional (nonclinical) studies to For personal use only 1Q27 meet requirements for marketin
Slide 10: Summary: Investment Opportunity with Broad Pipeline
Summary: Investment Opportunity with Broad Pipeline • SedRx provides a largely de-risked, near-term investment opportunity in a significant and growing market • SedRx general anaesthetic product has clear differentiated advantages over current approved products in an aging population For personal us
Slide 11: Financial Summary
Financial Summary Financial Information Key Financial Metrics 12 Month Share Price Performance Ticker Code ASX: BIT Ticker Code ASX: BIT Share Price (2 Sept 26) A $0.0025 Share Price (15 Sept 2014) A $0.115 For personal use only Market cap A $8.35 million 12 Month Trading Range A $0.001-0.005 Market
Slide 12: Biotron Limited
For personal use only BIOTRON LIMITED | ASX:BIT Michelle Miller Managing Director mmiller@biotron.com.au +61 412 313 329 www.biotron.com.au
Biotron — Biotech Showcase, Melbourne (September 2026) on 6ix